Advertisement

© 2010

Chronic Myeloid Neoplasias and Clonal Overlap Syndromes

Epidemiology, Pathophysiology and Treatment Options

  • Richard Greil
  • Lisa Pleyer
  • Viktoria Faber
  • Daniel Neureiter
  • Comprehensive review on pathophysiology and therapy on Chronic Myeloid Diseases

  • Easy to follow diagnostic algorithms on the clinical management

  • Well illustrated with clinical photos, clear graphics and illustrations

Book

Table of contents

  1. Front Matter
    Pages i-xi
  2. Lisa Pleyer, Victoria Faber, Daniel Neureiter, Daniel Neureiter, Richard Greil
    Pages 15-50
  3. Lisa Pleyer, Daniel Neureiter, Richard Greil
    Pages 51-79
  4. Nikolas von Bubnoff, Lisa Pleyer, Daniel Neureiter, Victoria Faber, Justus Duyster
    Pages 117-152
  5. Lisa Pleyer, Daniel Neureiter, Victoria Faber, Richard Greil
    Pages 153-222
  6. Lisa Pleyer, Daniel Neureiter, Victoria Faber, Richard Greil
    Pages 223-233
  7. Thomas Melchardt, Lukas Weiss, Lisa Pleyer, Daniel Neureiter, Victoria Faber, Richard Greil
    Pages 235-258
  8. Lisa Pleyer, Daniel Neureiter, Richard Greil
    Pages 281-288
  9. Back Matter
    Pages 289-292

About this book

Introduction

Introduction The understanding of the genetic, epigenetic, immuno- well as for practicing hematologists or oncologists. logical and biological causes of myeloproliferative dis- Each chapter follows a similar architecture and leads orders has substantially improved in the last few years. through epidemiology, genetic and molecular causes, Together with refined tools in pathology, the successful hematological and clinical findings, prognostic factors establishment of mouse models mimicking at least some and current treatment approaches of the diseases. of the myeloproliferative disorders, and murine models Effort has been made to point out the evolving field of novel drugs in this arena but simultaneously diff- allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to entiate between standard and experimental treatment ever increasing numbers of modified classification approaches. schemes. It is therefore important for the heamtologist Together with the co-editors and all the authors of or oncologist to keep up with this rapid change in classi- the various chapters I hope that the readers of the book fication language, the upcoming of new entities or differ- will enjoy reading and benefit from the information entiation between, or subclassification of, rare diseases provided.

Keywords

Myelodysplastic Syndroms Myeloproliferative Disorders Myeolid Disorders Therapy anemia cell epidemiology leukemia lymphoma pathophysiology physiology

Editors and affiliations

  • Richard Greil
    • 1
  • Lisa Pleyer
    • 1
  • Viktoria Faber
    • 1
  • Daniel Neureiter
    • 2
  1. 1.Universitätsklinik für Innere Medizin IIIParacelsus Medizinische PrivatuniversitätSalzburgAustria
  2. 2.Universitätsinstitut für PathologieParacelsus Medizinische PrivatuniversitätSalzburgAustria

About the editors

Head of the Third University Clinic for Internistic Oncology, Hematology,  Hemostasiology, Rheumatology and Infectiology at the Paralcesus Medical University in Salzburg
Head of the Labaratory for Immunological and Molecular Cancer Research, Salzburg

Bibliographic information

  • Book Title Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
  • Book Subtitle Epidemiology, Pathophysiology and Treatment Options
  • Authors Richard Greil
    Lisa Pleyer
    Daniel Neureiter
    Viktoria Faber
  • DOI https://doi.org/10.1007/978-3-211-79892-8
  • Copyright Information Springer-Verlag Vienna 2010
  • Publisher Name Springer, Vienna
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-3-211-79891-1
  • Softcover ISBN 978-3-7091-2003-3
  • eBook ISBN 978-3-211-79892-8
  • Edition Number 1
  • Number of Pages XI, 295
  • Number of Illustrations 0 b/w illustrations, 0 illustrations in colour
  • Topics Oncology
    Internal Medicine
    Blood Transfusion Medicine
  • Buy this book on publisher's site
Industry Sectors
Biotechnology
Health & Hospitals
Oncology & Hematology
Pharma